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Abstract
Background: The clinical heterogeneity of the 22q11.2 Deletion Syndrome (22q11.2DS – OMIM, #188400 and
#192430) is a universal challenge leading to diagnostic delay. The aim of this study was to evaluate a low cost
strategy for the diagnosis of this condition based upon clinical criteria previously reported. Health professionals,
who collected clinical data, from twelve centers were trained in those criteria, which were summed through an
online application (CranFlow).
Results: Clinical and laboratorial data of 347 individuals registered from 2008 to 2017 in the Brazilian Database on
Craniofacial Anomalies/22q11.2 Deletion Syndrome, were reviewed. They were divided in two groups: (I) 168
individuals investigated before the definition of the criteria and (II) 179 individuals investigated after the criteria
application. All of them were investigated for 22q11.2DS by Fluorescent in situ Hybridization (FISH) and/or Multiplex
Ligation Probe-dependent Amplification (MLPA), detecting 98 cases with 22q11.2DS. Among the individuals with
22q11.2DS in Group II, 42/53 (79.25%) fulfilled the proposed criteria against 11/53 (20.75%) who did not fulfill them
(p < .0001). The association of congenital heart diseases with high predictive value for 22q11.2DS and hypernasal
voice were significantly associated to the presence of 22q11.2DS (p = 0.0172 and p < .0001, respectively). In addition,
22q11.2DS was confirmed 3.82 more times when the individuals fulfilled the proposed criteria. Of the 249 cases
negative for the typical deletion in 22q11.2, Chromosomal Microarray Analysis (CMA) was performed in 132
individuals and detected pathogenic alterations at other genomic regions in 19 individuals, and variants of
uncertain clinical significance in 31 cases.
Conclusions: Therefore, a locus-specific approach could be used to individuals with positive criteria as a cost-
effective alternative for 22q11.2DS diagnosis. The authors discuss advantages and suggest ways of implementing
this approach to investigate 22q11.2DS in a public health system.
Keywords: 22q11.2 deletion syndrome, Clinical criteria, Diagnosis, Public health, Fluorescence in situ hybridization,
Multiplex ligation probe-dependent amplification, Chromosomal microarray analysis
Background
The 22q11.2 Deletion Syndrome (22q11.2DS – OMIM,
#188400 and #192430) is the most common deletion in
humans, with an estimated incidence of 1/4.000 to 1/
5.000 births [1]. There is a wide range of clinical signs
associated with this condition, being the most frequent:
congenital heart disorders (mainly conotruncal defects),
palatal anomalies, hypocalcemia, immunological defi-
ciency, learning disability and developmental delay,
behavioral and psychiatric disorders [2–7].
The diagnosis is based on the detection of the typical
deletion in the 22q11.2 region, which comprises from
1.5Mb to 3.0 Mb in size, without recognizable pheno-
typic differences between them [7, 8]. The evolution of
laboratory methods in genetics has brought several diag-
nostic possibilities for this microdeletion, however, the
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wide clinical heterogeneity of this syndrome hampers
the diagnosis.
In the mid-1990s, the Fluorescence in situ Hybridization
(FISH) technique using a locus-specific probe for the
22q11.2 chromosome region was described, and for many
years it has been considered as the “gold standard” for de-
tecting this microdeletion [9–11]. This allows the detec-
tion of the proximal and common deletion in 22q11.2 and
is the most widespread method. Nevertheless, a negative
FISH result does not totally exclude the diagnosis of
22q11.2DS, since minor or atypical deletions may occur
within the typically deleted region [12, 13]. In this context,
technologies in molecular biology have allowed the devel-
opment of different methods, such as the Multiplex
Ligation-dependent Probe Amplification (MLPA) tech-
nique, an efficient, rapid and sensitive method for the
diagnosis of 22q11.2DS, which detects both microdele-
tions and microduplications of this region, as well as alter-
ations in other chromosomal regions that have been
associated with the phenotype of this syndrome [10, 14].
More recently, methods for genome-wide analysis have
achieved considerable visibility in the field of genetics, and
currently, the chromosomal microarray analysis (CMA) is
the first-tier technique for the investigation of the deletion
in 22q11.2 [15]. Yet, its large-scale diffusion still fights the
difficulties of high cost infrastructure and inputs in some
countries.
The number of cases with the 22q11.2 deletion,
among those with a clinical suspicion, is variable and
dependent on the design of the study, varying from
4.0 to 78.2% [2, 8, 16–18]. Because of the clinical het-
erogeneity, even with different molecular techniques
available, the time of diagnosis is still late, delaying
the appropriate clinical management of the individual and
genetic counseling of the family [2, 19, 20]. Outlining the
clinical and/or phenotypic aspects that indicate 22q11.2
deletion screening and genotype-phenotype correlation
studies have been a challenge and theme of interest to dif-
ferent researchers [9, 21–23].
In 2013, Monteiro and coworkers proposed clinical
criteria to proceed with a laboratory investigation for
22q11.2DS, based upon a review of the literature and
evaluation of 193 individuals. The main differential as-
pect of this proposal is the clinical general approach,
which includes different manifestations of this microde-
letion [22]. This article addresses the results of using
these criteria in a group of 347 individuals with clinical
suspicion of 22q11.2DS recorded in the Brazilian Data-
base on Craniofacial Anomalies/22q11.2DS.
Patients and methods
The cohort was composed of 347 individuals with clin-
ical suspicion of 22q11.2DS or at least one major
22q11.2DS manifestation registered in the Brazilian
Database on Craniofacial Anomalies/22q11.2 Deletion
Syndrome (BDCA) from 2008 to 2017. Health profes-
sional participants of the Brazil’s CranioFacial Project
(BCFP) evaluated all individuals. They were investigated
for the 22q11.2DS by FISH with the TUPLE1 probe (Cyto-
cell Aquarius® or Visys Abbott©) and/or MLPA with the
P250 kit (MRC-Holland®, Amsterdam, the Netherlands).
The 347 individuals were evaluated for the proposed
criteria in two periods. The first one included 168 indi-
viduals described by Monteiro et al. [22], to whom a
standard clinical protocol including major features and
some minor traits of 22q11.2DS had been applied
(Group I). Individuals from Monteiro et al. [22] manu-
script with schizophrenia as the major manifestation
(Group IV of the original manuscript in which the cri-
teria were proposed) were excluded since this study had
a dysmorphologic approach. The second group was
composed by individuals evaluated according to the clin-
ical criteria proposed by the same authors, as described
in Table 1 (Group II) [22].
Standardized clinical and complementary data were
collected through a web-based application (CranFlow:
Craniofacial anomalies: registration, flow, and manage-
ment) [24]. It was developed by this research group for
general craniofacial anomalies with a specific area for
22q11.2DS suspicion, in which data are recorded and
the sum of features is automatically performed according
to the proposed criteria by Monteiro [22]. Follow-up
consultations are also recorded, allowing recognition of
the individual’s and the diseases’ natural history, as well
as updating the clinical manifestations and its sum, and
differential diagnosis. This tool is available for interested
researchers. Before data collection for Group II, all par-
ticipant health professionals were trained to use the
CranFlow.
Data analyses were performed using The Statistical
Analysis System (SAS) for Windows, version 9.4 (SAS
Institute INC, 2002–2008, Cary, NC, USA). Categorical
variables were investigated by the Chi-Square test and
Fischer’s exact test, when necessary. The logistic regres-
sion analysis was used to evaluate the factors that dis-
criminate the 22q11.2DS among those proposed by
Monteiro et al. [22]. The significance level was set at 5%
(p < 0.05). The values of odds ratio (OR) and confidence
interval (CI) were computed.
Additionally, 132 negative cases for 22q11.2DS had
CMA through different platforms performed during
clinical routine. All of these had CMA data reanalyzed
in this study, following an “in-house” workflow based on
standard recommendations [25].
Results
The total sample included 347 individuals (186 females,
161 males) with clinical suspicion of 22q11.2 deletion
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syndrome. Group I was composed of 168 individuals (88
females, 80 males) and mean age at inclusion in BDCA
was 11.6 years old. Group II included 179 individuals (98
females, 81 males) and the mean age at inclusion in
BDCA was 7.9 years old. Overall, there was a difference
of the mean age at inclusion among Groups I and II
(p < .0001), indicating better access to a specialized ser-
vice for group II. Among the individuals who were posi-
tive for 22q11.2DS in Groups I and II, the mean age at
diagnosis was 12.7 against 8.8 years old (p = 0.0344), re-
spectively. Table 2 shows the profile of the total sample
comparing the proposed criteria and the laboratorial
data in both groups.
Comparing individuals with 22q11.2DS in the Groups
I and II, the percentage at diagnosis of the 22q11.2DS
was 26.79% against 29.61%, respectively (p = 0.5593).
However, in Group II, the presence of 22q11.2 deletion
in individuals with positive criteria (42/99–42.42%) was
significant when compared to the number of individuals
negative for the criteria (11/80–13.75%) (p < .0001). The
same comparison in Group I, did not show a significant
difference, 31/96 (32.29%) against 14/72 (19.44%), re-
spectively (p = 0.0628).
Among the 99 individuals with positive criteria in
Group II, the general distribution according to different
criteria groups proposed by Monteiro et al. [22] were 10
for column 01 (10.10%), 24 for column 02 (24.24%), 6 for
column 03 (6.06%) and 59 for the combination between
columns 02 and 03 (59.60%) (p = 0.0004). Moreover, the
association of a congenital heart disease with high
Table 2 Description of the total sample, Groups I and II and positivity according to criteria proposed by Monteiro et.al [22]
Positive 22q11.2DS Negative 22q11.2DS Total p value*
Total sample 98/347 (28.24%) 249/347 (71.76%) 347 (100%) <.0001
Positive for criteria 73/347 (21.04%) 122/347 (35.16%) 195/347 (56.20%) –
Negative for criteria 25/347 (7.20%) 127/347 (36.60%) 152/347 (43.80%) –
Group I* 45/168 (26.79%) 123/168 (73.21%) 168/347 (48.41%) 0.0628
Positive for criteria 31/96 (32.29%) 65/96 (67.71%) 96/168 (57.14%) –
Negative for criteria 14/72 (19.44%) 58/72 (80.56%) 72/168 (42.86%) –
Group II - Total 53/179 (29.61%) 126/179 (70.39%) 179/347 (51.59%) <.0001
Positive for criteria 42/99 (42.42%) 57/99 (57.58%) 99/179 (55.31%) –
Negative for criteria 11/80 (13.75%) 69/80 (86.25%) 80/179 (44.69%) –
*p value according to main groups
Table 1 Clinical guidelines for screening the 22q11.2 deletion proposed by Monteiro et al. [22]
Column 1 – Absolute indications
for confirmatory testing
Column 2 – Core features of the 22q11.2DS Column 3 – Associated features of the
22q11.2DS
Any item from Column 1 At least two items from Column 2 OR one
item from Column 2 and at least two items
from Column 3
Two or more items from Column 3 and one
from Column 2 OR at least four items from
Column 3a
A. Cardiac malformation with high predictive
value for the deletion: Interruption of aortic
arch type B, Truncus arteriosus and/or
Ventricular Septal defect with pulmonary atresia
(Tetralogy of Fallot with pulmonary atresia)
B. Neonatal hypocalcemia secondary to
idiopathic hypoparathyreoidism
C. Other Conotruncal Heart defects: Classic
Tetralogy of Fallot, Ventricular Septal Defect
posterior malalignement, Ventricular Septal
Defect Subarterial/Subpulmonary and/or
Aortic Coarctation
D. Palatal alterations: Velopharyngeal
Insufficiency, Overt or submucous cleft
palate and/or cleft lip/palate
E. Immunodefficiency confirmed by
labaratorial tests and/or thymic alterations
(hypoplasia/aplasia)
F. Typical Face with four or more characteristic
dysmorphisms, being at least three among the
following: Long face, hooded eyelids, tubular





development delay and/or learning
disability
I. Cardiovascular abnormalities: Aortic arch
alterations and/or pulmonary arterial
tree alterations
J. Two or more suggestive dysmorphisms
(> = 2 years-old) OR One or more suggestive
dysmorphisms (<= 2 years-old)
K. Hypernasal tone of voice
L. Other cardiac defects: Other types of
Ventricular Septal defect, Transposition of
Great Arteries, Double right-outlet ventricle,
Atrial septal defect and/or Patent ductus
arteriosus
M. Other Palatal alterations: Isolated bifid
uvula and/or Cleft lip
N. Genitourinary malformations
a Patients younger than 1 year-old: One or more items from Column 3 and at least one item from Column 2 OR four or more items from Column 3 a Patients
younger than 1 year-old: One or more items from Column 3 and at least one item from Column 2 OR four or more items from Column 3
Sgardioli et al. Orphanet Journal of Rare Diseases          (2019) 14:123 Page 3 of 8
predictive value for 22q11.2DS (items A) and hypernasal
tone of voice (item K) was strongly indicative of
22q11.2DS in Group II (p = 0.0172 and p < .0001, respect-
ively).
Among the confirmed cases for 22q11.2DS in the
Group II, the analysis of the proposed criteria, positive
(42/99–42.42%) or negative (11/80–13.75%), revealed
that the criteria were significant (p < .0001) and repre-
sents an increased diagnosis of 3.82 times. Table 3 shows
the results of the analysis by the items of criteria.
Of the 249 negative cases for 22q11.2DS, 117 are still in
follow up and 132 were investigated through CMA, which
detected chromosomal imbalances at other genomic re-
gions in 19 individuals, including five atypical deletions in
22q11.2. Besides, variants of uncertain clinical significance
(VUS) were detected in 31 cases, which require other la-
boratory techniques for conclusion, such as three cases
suggestive of Uniparental Disomy (UDP) which are still
under investigation. CMA was normal 82 cases.
Discussion
Testing the clinical criteria for 22q11.2DS
Phenotypic heterogeneity of the 22q11.2DS is known to
pose difficulties to clinical suspicion of this condition,
especially in cases with mild manifestations. Most previ-
ous studies on this subject focused on groups of individ-
uals with similar clinical signs. This approach does not
allow reaching a general consensus for the investigation
of 22q11.2DS, leading to difficulties in clinical practice
[2, 7, 19, 26, 27].
Table 3 Comparison among different items from the criteria proposed by Monteiro et al. [22] in Group II
Items of criteria
according to Table 1
Positive criteria Total of Individuals Negative for 22q11.2DS Positive for 22q11.2DS p value ORa IC95%b
A Yes 09 04 (3.47%) 05 (9.43%) 0.0949 3.177 0.818–12.336
No 170 122 (96.83%) 48 (90.57%) – 1.000 –
B# Yes – – – – – –
No – – – – – –
C Yes 22 15 (11.90%) 07 (13.21%) 0.9086 1.126 0.431–2.943
No 157 111 (88.1%) 46 (86.79%) – 1.000 –
D Yes 101 65 (51.59%) 36 (67.92%) 0.0459 1.987 1.013–3.901
No 78 61 (48.41%) 17 (32.08%) – 1.000 –
E Yes 11 08 (6.35%) 03 (5.66%) 0.8610 0.885 0.225–3.474
No 168 118 (93.65%) 50 (94.34%) – 1.000 –
F Yes 22 13 (10.32%) 09 (16.98%) 0.2193 1.778 0.710–4.455
No 157 113 (89.68%) 44 (83.02%) – 1.000 –
G## Yes – – – – – –
No – – – – – –
H Yes 76 48 (38.10%) 28 (52.83%) 0.0702 1.820 0.952–3.480
No 103 78 (61.90%) 25 (47.17%) – 1.000 –
I Yes 03 02 (1.59%) 01 (1.89%) 0.8868 1.192 0.106–13.438
No 176 124 (98.41%) 52 (98.11%) – 1.000 –
J Yes 94 61 (48.41%) 33 (62.26%) 0.0919 1.758 0.912–3.388
No 85 65 (51.59%) 20 (37.74%) – 1.000 –
K Yes 66 34 (26.98%) 32 (60.38%) <.0001 4.123 2.096–8.111
No 113 92 (73.02%) 21 (39.62%) – 1.000 –
L Yes 66 44 (34.92%) 22 (41.51%) 0.4048 1.323 0.685–2.553
No 113 82 (65.08%) 31 (58.49%) – 1.000 –
M Yes 08 07 (5.56%) 01 (1.89%) 0.3015 0.327 0.028–2.725
No 171 119 (94.44%) 52 (98.11%) – 1.000 –
N Yes 11 10 (7.94%) 1 (1.89%) 0.1578 0.223 0.028–1.788
No 168 116 (92.06%) 52 (98.11%) – 1.000 –
The criteria groups are described according to the criteria proposed by Monteiro et.al. [22] in Table 1
aOR - odds ratio for deletion
bIC95% - ratio confidence interval. B #: there were not enough cases for analysis; G ##: individuals with schizophrenia were not evaluated in this study
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An important aspect of the clinical criteria proposed
by Monteiro et al. [22] is the inclusion of distinct mani-
festations of 22q11.2DS, as well as different combina-
tions of those clinical signs, allowing a wider approach
to patient selection for testing and phenotypic recording
[22]. However, its applicability has never been tested.
Therefore, this is the first study using these criteria.
In addition, this study has another differential that can
aggregate in clinical practice and in public health, which
is the introduction of an online tool - CranFlow, which
standardizes the data collection according to those cri-
teria, as well as facilitates their summation by groups
and columns for each consultation, since it is performed
automatically in each evaluation [24].
The analysis of the total sample revealed the presence
of 22q11.2DS in 98 individuals, of whom 73 (74.49%)
fulfilled the proposed criteria and 25 (25.51%) did not.
According to these results, the proposed criteria would
contribute to the diagnostic conclusion of 2/3 of
22q11.2DS cases. Differences among Groups I and II
probably were related to the inclusion criteria, as well as
to the strategy of data collection. Group I was composed
of individuals investigated according to clinical suspicion
of 22q11.2DS by a medical geneticist, or by the presence
of at least one major manifestation of this condition.
Moreover, clinical data recorded included mainly more
characteristic manifestations of the 22q11.2DS. It is
therefore possible that some individuals from Group I
had additional minor features of this disorder that were
not reported by the health care provider. Conversely,
Group II was designed including training for recognition
and recording of a wide spectrum of 22q11.2DS features
based upon the proposed criteria.
Therefore, the results from Group II are more reliable
when it comes to testing the proposed criteria. They dem-
onstrate a significant difference in patients who tested
positive for 22q11.2DS and fulfill the proposed criteria, be-
ing a large proportion of those individuals with a combin-
ation of columns 02 and 03, i.e., patients with one core
manifestation plus associated (although more unspecific)
features. Overall, the criteria increased by 3.82 times the
diagnosis when comparing individuals with confirmed
22q11.2DS positive or negative for the proposed criteria,
suggesting its applicability on large scale.
Despite sample size, which did not allow to accurately
identify statistical significance for each individual item
from the three columns, it was possible to determine
that the presence of a congenital heart disease with high
predictive value for 22q11.2DS (item A) and hypernasal
tone of voice (item K) was strongly indicative of
22q11.2DS in Group II (p = 0.0172 and p < .0001, respect-
ively), suggesting consistency of the proposed criteria.
The criteria proposed by Monteiro et al. [22] show an
alternative for reducing the age at diagnosis, which is a
current and universal theme. The mean age at diagnosis
of 22q11.2DS in two Brazilian studies were around 10
years old [2, 20], which is similar to studies of other
countries according to Palmer and coworkers [19].
Mean age at inclusion in the database among Groups I
and II was significantly decreased, but still did not af-
fected the mean age at 22q11.2DS diagnosis. This could
be explained by difficulties in access to genetic clinical
evaluation and laboratory investigation in Brazil [28–33].
Even so, the sample was not large enough to verify the
repercussion on age at diagnosis of 22q11.2DS.
Considering the duration of the study, the prevalence
of 22q11.2DS and the comprehensiveness of the criteria,
the results described here seem quite promising. The ex-
tended application in different populations could poten-
tially bring more insight into the current research
strategy. In the long term, it also could contribute to the
refinement or modification of the criteria herein tested.
Diagnosis of 22q11.2DS and public health
The design of this study is consistent and allows inter-
pretations and immediate proposals for health care. A
highlight is the laboratory approach that may be
interesting for public health application, especially in
countries where access to technology, considering infra-
structure and inputs, is limited due to high costs.
Considering that 73 out of the 98 patients who tested
positive for the typical deletion fulfilled the proposed cri-
teria, a hierarchical laboratory approach could be applied
in which, in the presence of proposed clinical criteria,
locus-specific tests, such as FISH and MLPA, would be
primary used. Despite international recommendations to
use CMA as first-tier test for individuals with intellectual
disability (ID) and/or multiple congenital anomalies
(MCA) [34], the approach based on training for pheno-
typic recognition and use of a locus-specific test would
allow for earlier diagnosis of a greater number of indi-
viduals with less financial impact. It would be of particu-
lar interest in regions in which expenditures with
healthcare are scarce.
As an example, an estimated comparison of costs for
CMA and locus-specific tests was described. These costs
were based on the values indicated and published by the
National Committee for the Implantation of Technology
(Comitê Nacional de Implantação de Tecnologia - CON-
ITEC) from the Unified Health Care System (Sistema
Único de Saúde - SUS) describing laboratory procedures
for the diagnosis of rare diseases associated with con-
genital anomalies. The converted values are equivalent
to R$ 3.70 (Brazilian currency - Real - R$).
Currently, the CMA is the first-tier screening test indi-
cated for the investigation of genomic imbalances, in in-
dividuals with multiple congenital anomalies and (or)
developmental delay / intellectual deficiency. The value
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proposed by CONITEC for CMA test is U$ 540.54,
which represents U$ 540,540.54 for the investigation of
1000 individuals. The values estimated in the same
document for the FISH and MLPA methods present the
cost of U$ 55.39 and U$ 52.14 per test respectively.
Adopting the cost of U$ 54.05 for locus-specific test, the
investigation of 1000 individuals would have an initial
cost of U$ 54,054.05. Applying the 42.42%, of positivity
rate of the individuals who fulfilled the criteria of Group
II in the present study, complementary investigation by
CMA for the other 576 individuals without 22q.11.2DS
would add U$ 311,351.35. Therefore, the final cost using
the proposed approach would be U$ 365,405.41 against
U$ 540,540.54 with CMA as the first-tier diagnostic test.
It represents a saving of U$ 175,135.13, which allows a
significant economic impact.
Jehee et al. [35] also showed that the application of
locus-specific tests as first-tier tests proved to be quite
effective and is an important alternative for diagnostic
screening in countries where health care costs are
scarce. In 2014, Geddes and colleagues carried out a
cost-effectiveness survey and proposed that each institu-
tion/system should evaluate the results of its genetic
tests, within its possibilities, to develop protocols of high
yield within a cost-effective standard [36].
In this context, applying the proposed criteria com-
bined with initial screening by locus-specific tests,
such as FISH or MLPA, can prove to be an important
strategy for the initial diagnostic investigation of
22q11.2DS in countries where major financial con-
straints are an issue or even to optimize financial re-
sources in health care.
The present study allowed the diagnosis of 98 individ-
uals with 22q11.2DS and 19 more individuals with gen-
omic imbalances in other regions by CMA. In long time,
recording this data in CranFlow would allow recognize
disorders which overlap with 22q11.2DS. In addition, the
reanalysis of CMA in this study showed the importance
of the standardization of CMA data analysis, as has been
demonstrated by other authors [25, 37]. All these data
shows important points for discussion for public health
regarding 22q11.2DS and other chromosomal disorders
detected by CMA.
It is noteworthy that, all the diagnostic methods de-
scribed in this work have advantages and disadvantages,
being necessary the evaluation of their applicability, as
well as the local infrastructure resources must be consid-
ered. CMA, although requiring more technological
equipment, allows conclusion in around 15 to 20% of
cases [34]. In this study, CMA resulted in increased
diagnostic rate, which is in accordance to the report by
Koczkowska and coworkers that described an increase in
diagnostic yield by approximately 12% [23]. Additionally,
CMA detects cases in which other molecular and
cytogenetic techniques will be needed for definite con-
clusion, thus demanding a specialized laboratory.
Considering the current options for 22q11.2 deletion
testing (locus-specific or genome wide methods), individ-
uals meeting the proposed criteria could be offered a
locus-specific approach, whereas individuals not fulfilling
them would probably benefit from a genome wide
method, such as CMA. In view of the global discrepan-
cies in access for genetic tests, this strategy could be a
cost-effective choice for 22q11.2DS diagnosis.
The data obtained evidence the difficulties in 22q11.2DS
diagnosis and reinforces the phenotypic heterogeneity of
this condition, which clinically overlaps with other gen-
omic alterations. The proposed approach with hierarchical
use of tests and centralization of more elaborate labora-
tory techniques, as well as standardization of unified pat-
tern of analysis and interpretation of data, is a relevant
strategy for diagnosis in any public health system.
Conclusion and final suggestions
Considering the proposed strategy for 22q11.2DS diag-
nosis in public health care, the following suggestions
could be adopted: a) training of health care provider
teams; b) applying proposed clinical criteria and using
CranFlow online tool to record clinical data and follow
up patients with 22q11.2DS suspicion; c) hierarchy of
genetic tests where CMA is not readily available as the
first-tier technique; and d) centralization for specialized
techniques; e) standardizing the analysis and interpret-
ation of genetic data and f) creation of a national regis-
try to optimize research resources in planning public
health policies for the diagnosis of 22q11.2DS.
These suggestions may bring important evidences for
public health for 22q11.2DS diagnosis, such as recogni-
tion and importance of rare features, as well as the dif-
ferential diagnosis of this condition, and the economic
impact of the approach herein proposed.
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